

# Webcast: Year-End FCA Updates for Life Sciences Companies

Webcasts | February 25, 2025

Looking back at 2024 and forward to the new year, False Claims Act (FCA) enforcement in the life sciences industry appears likely to remain a top priority for regulators—despite the significant flux at the U.S. Department of Justice. With significant settlements, increased whistleblower actions, and evolving legal interpretations, companies must be prepared for heightened scrutiny of pricing, reimbursement, research, patient support, and marketing practices, and the emerging application of the FCA to companies with DEI programs. This webcast provides a review of key FCA developments from 2024 and a look ahead to emerging enforcement trends and regulatory priorities affecting pharmaceutical, biotech, and medical device companies in the transition to the Trump Administration.

**MCLE CREDIT INFORMATION:** This program has been approved for credit in accordance with the requirements of the New York State Continuing Legal Education Board for a maximum of 1.5 credit hours, of which 1.5 credit hours may be applied toward the areas of professional practice requirement. This course is approved for transitional/non-transitional credit. Attorneys seeking New York credit must obtain an Affirmation Form prior to watching the archived version of this webcast. Please contact [CLE@gibsondunn.com](mailto:CLE@gibsondunn.com) to request the MCLE form. Gibson, Dunn & Crutcher LLP certifies that this activity has been approved for MCLE credit by the State Bar of California in the amount of 1.5 hours in the General Category. California attorneys may claim “self-study” credit for viewing the archived version of this webcast. No certificate of attendance is required for California “self-study” credit.

**PANELISTS:** **John D.W. Partridge**, a Co-Chair of the FDA and Health Care Practice Group and Chambers-ranked white collar defense and government investigations lawyer, focuses on government and internal investigations, white collar defense, and complex litigation for clients in the life science and health care industries, among others. John has particular experience with the Anti-Kickback Statute, the False Claims Act, the Foreign Corrupt Practices Act, and the Federal Food, Drug, and Cosmetic Act, including defending major corporations in investigations pursued by the U.S. Department of Justice and the U.S. Securities and Exchange Commission. **Jonathan M. Phillips** is a partner in the Washington, D.C. office where he is a member of the firm's litigation department and Co-Chair of the FDA and Health Care Practice Group and False Claims Act/Qui Tam Defense Practice Group. A former DOJ Trial Attorney, his practice focuses on FDA and health care enforcement, compliance, and litigation, as well as other white collar enforcement matters and related litigation. Mr. Phillips is ranked nationally as a leading False Claims Act practitioner by *Chambers USA*. **Jake M. Shields** is a partner in the Washington, D.C. office and a member of the firm's False Claims Act, FDA & Health Care, Life Sciences, Cybersecurity, Government Contracts, Antitrust, Litigation, and White-Collar Defense and Investigations Practice Groups. An expert in the False Claims Act (FCA) and the Financial Institutions Reform, Recovery, & Enforcement Act (FIRREA), Jake was a Senior Trial Counsel at the Civil Frauds Section of the U.S. Department of Justice where, over an eight-year career spanning administrations of both major political parties, he investigated and litigated FCA and FIRREA cases on behalf of the federal government. **Blair Watler** is a senior associate in the Washington, D.C. office. She practices in the firm's Litigation Department with a focus on white collar defense and investigations. Blair's experience includes representing and advising clients in government investigations and enforcement actions by the U.S. Department of Justice and the U.S. Securities and Exchange Commission involving the Foreign Corrupt Practices Act, the False Claims Act, and the Federal Food, Drug, and Cosmetic Act. © 2025 Gibson, Dunn & Crutcher LLP. All rights

## Related People

[John D.W. Partridge](#)

[Jonathan M. Phillips](#)

[Jake M. Shields](#)

[Blair Watler](#)

# GIBSON DUNN

reserved. For contact and other information, please visit us at [www.gibsondunn.com](http://www.gibsondunn.com).  
Attorney Advertising: These materials were prepared for general informational purposes only based on information available at the time of publication and are not intended as, do not constitute, and should not be relied upon as, legal advice or a legal opinion on any specific facts or circumstances. Gibson Dunn (and its affiliates, attorneys, and employees) shall not have any liability in connection with any use of these materials. The sharing of these materials does not establish an attorney-client relationship with the recipient and should not be relied upon as an alternative for advice from qualified counsel. Please note that facts and circumstances may vary, and prior results do not guarantee a similar outcome.

## Related Capabilities

[False Claims Act / Qui Tam Defense](#)

[FDA and Health Care](#)